The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

EU Logoefpia Logo


IMI launches €115m Calls for proposals

IMI has now launched its 3rd and 4th Calls for proposals under IMI 2, with topics on remote assessment, type 2 diabetes, neuropsychiatry, vaccine manufacture, pertussis vaccines, patient engagement and adaptive pathways.



  • A life-saving technology

    IMI project SUMMIT has developed an ultrasound device to identify patients at imminent risk of a heart attack or stroke

    ... more
  • Action on autism

    Watch a video on how EU-AIMS is developing tools to boost our understanding of autism, paving the way for new treatments

    ... more
  • Get on-course!

    With over 5 000 courses, on-course, run by the EMTRAIN project, is Europe's most comprehensive biomedical R&D postgrad course portal

    ... more
  • Innovation in action

    IMI's 46 projects have a combined budget of €1.6 billion and are tackling some of the toughest challenges in drug development.

    ... more
  • Patient power!

    EUPATI is developing educational resources that will empower patients to engage more effectively in the drug research and development process

    ... more
  • Schizophrenia breakthrough

    NEWMEDS project research published in Nature reveals that genetic variants linked with schizophrenia have an impact in healthy carriers

    ... more
All projects


IMI is holding webinars on each topic of the IMI2 3rd and 4th Calls for proposals, as well as its new rules and procedures.

The webinars take place in December 2014 and January 2015.

For registration and more information, visit the webinar page


  • 19/12/2014 : RT @s_liege: First students given access to the @Eu2P eLearning platform for the pilot #SafeSciMET course under @IMI_JU #imitrain project f…
  • 19/12/2014 : RT @UBIOPRED: U-BIOPRED patient reps take part in European Medicines training day. Read Val's report at @EMA_News
  • 19/12/2014 : RT @Open_PHACTS: Some great examples of how Open PHACTS can help solve drug discovery problems:

Follow us on Twitter